Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NGM282 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

NCT04828265
View directory record Official record
Conditions
Healthy Male
Interventions
Aldafermin
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

NCT02649062
View directory record Official record
Conditions
Functional Constipation
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

NCT02135536
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NCT03912532
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

NCT02704364
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Sacramento, California • San Clemente, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
Interventions
Aldafermin, Placebo
Drug
Lead sponsor
Michael Camilleri, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
Aldafermin
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

NCT04210245
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
aldafermin, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282, Placebo
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

NCT04179630
View directory record Official record
Conditions
Impaired Renal Function
Interventions
Aldafermin (NGM282)
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 1, 2026, 1:55 PM EDT